# Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome

> **NCT01676597** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 80 (estimated)

## Conditions studied

- Hepatopulmonary Syndrome

## Interventions

- **DRUG:** pentoxifylline and rifaximin
- **DRUG:** Pentoxifylline and placebo

## Key facts

- **NCT ID:** NCT01676597
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2013-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676597, "Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01676597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*